This book represents a remarkably look at the present and possible future of biotecnology research in the wake of the mapping of the human genome. The central tenet of Celera Diagnostics (the California biotech company whose formative work during 2003 is the focus of the book) is that the emergent knowledge about the genome, with its profound implications for human health, can now be turned into a powerful diagnostic apparatus - one that will yield breakthrough diagnostic and therapeutic products (and, potentially, profit). Celera´s efforts - assuming they succeed - may fundamentally reshape the fabric of how health and health care are understood, practiced, and managed. Presenting a series of interviews with all of the key players in Celera Diagnostics, Paul Rabinow and Talia Dan-Cohen open a fascinating window on the complexity of corporate scientific innovation.